查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1736748

2026-2032 年体外膜氧合市场（按零件、服务、病患类型、应用和地区划分）

Extracorporeal Membrane Oxygenation Machine Market By Component (Pumps, Cannula), By Services (Veno-Venous, Veno-Arterial), By Patient Type (Adult, Pediatric), By Application (Respiratory, ECPR), And Region for 2026-2032
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

体外膜氧合（ECMO）市场评估-2026-2032

先进感测器和监测系统的不断发展和应用，能够即时评估和追踪患者参数，推动了体外膜氧合市场的成长。医疗保健产业的成长，尤其是在新兴地区的成长，为体外膜氧合市场创造了新的机会，预计2024年该市场的估值将超过6.2323亿美元，到2032年将达到约9.3281亿美元。

此外，技术进步也提升了医护人员使用ECMO设备的实践，促进了ECMO设备在各种临床环境中的广泛应用。这项技术提高了患者的存活率，预计2026年至2032年期间，该利基市场的复合年增长率将达到5.75%。

体外膜氧合市场定义/概述

体外膜氧合技术是指血液经由心肺机进行体外循环。这种方法可以有效去除二氧化碳，同时将富氧血液送回循环系统。血液经心臟右侧流入心肺机。之后，血液被重新加热并返回体内。

ECMO 是指将病患的血液引导至体外循环，使其氧合併去除二氧化碳，然后再回到体内。 ECMO 常用于治疗严重心臟衰竭、呼吸衰竭（例如急性呼吸窘迫症候群 (ARDS) 和肺炎）以及心血管手术后的併发症。 ECMO 越来越多地应用于新生儿和儿科护理，显着提高了患有先天性缺陷和严重呼吸窘迫的婴儿的存活率。 ECMO 能够暂时接管衰竭器官的功能，为医生提供了一个关键的窗口，以稳定患者病情并解决功能障碍的根本原因。

心臟病和呼吸系统疾病发生率的不断上升如何推动市场扩张？

心肺疾病的发生率不断上升是一个重大问题，凸显了加强医疗干预措施（包括体外膜氧合 (ECMO) 设备）的必要性。由于人口老化、久坐不动的生活方式、不良饮食习惯以及高血压、肥胖和糖尿病等危险因素的日益普遍，心臟衰竭、心肌梗塞和心臟麻痹等心臟疾病的发病率正在上升。由于这些疾病通常会导致危及生命的状况，而传统治疗方法无法奏效，因此，ECMO 系统在治疗潜在疾病的同时，透过维持氧合和循环功能，已成为维持生命的必要手段。

急性呼吸窘迫症候群(ARDS) 的特征是肺部小气囊内积液，抑制氧气有效输送至血液。 ARDS 可能发展为严重的呼吸系统疾病，需要外部辅助才能获得有效的呼吸支持。心源性休克是一种严重的疾病，其特征是心臟突然无法有效泵血以满足身体需求，如果不及时处理，可能导致器官衰竭。

患者数量的不断增长推动了对体外膜氧合（ECMO）设备的需求。 ECMO设备可以替代心臟和肺部，使这些重要器官休息和恢復。对于加护病房中那些对其他疗法无效的患者，这项技术已成为必不可少的治疗手段。心肺疾病盛行率的不断上升是影响ECMO设备市场的关键因素。

ECMO 设备和程序相关成本的上升是否会阻碍市场扩张？

体外膜氧合机（ECMO）在维持心臟衰竭衰竭患者生命方面发挥着至关重要的作用。 ECMO设备成本高昂，通常高达数十万人事费用，是其关键问题之一。此外，这种治疗方法需要高度专业的医疗团队，包括训练有素的灌注师、加护病房(ICU) 工作人员以及持续的患者监测，这增加了人员成本，并限制了能够提供ECMO治疗的医院数量。

这是因为其製造过程中采用了最尖端科技和创新材料。总成本也受到这些机器相关的维护和营运费用的影响。 ECMO治疗需要由外科医生、护士和鼓膜技师组成的医疗专业团队，这会增加治疗总成本。

目录

第 1 章全球体外膜氧合市场简介

  • 市场定义
  • 市场区隔
  • 调查时间表
  • 先决条件
  • 限制

第 2 章 已验证的市场研究调查方法

  • 资料探勘
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程
  • 业界专家的重要见解
  • 资料来源

第三章执行摘要

  • 市场概览
  • 生态测绘
  • 绝对的商机
  • 市场吸引力
  • 全球体外膜氧合装置市场区域分析
  • 全球体外膜氧合装置市场（按患者类型划分）（百万美元）
  • 全球体外膜氧合装置市场（按应用划分）（百万美元）
  • 全球体外膜氧合装置市场（按类型划分）（百万美元）
  • 全球体外膜氧合装置市场（按组件划分）（百万美元）
  • 未来市场机会
  • 全球市场区隔
  • 产品生命线

第四章 体外膜氧合装置全球市场展望

  • 体外膜氧合的全球演变
  • 驱动程式
    • 司机1
    • 司机2
  • 限制因素
    • 约束因素 1
    • 约束因素 2
  • 机会
    • 机会1
    • 机会2
  • 波特五力模型
  • 价值链分析
  • 定价分析
  • 宏观经济分析

5. 全球体外膜氧合装置市场（按部分）

  • 概述
  • 泵浦
  • 套管
  • 氧气供应
  • 配件
  • 控制器

6. 全球体外膜氧合装置市场（依服务）

  • 概述
  • 静脉-动脉
  • 静脉-维纳斯
  • 动脉-金星

7. 全球体外膜氧合装置市场（依患者型态）

  • 概述
  • 成人
  • 孩子们
  • 新生儿

8. 全球体外膜氧合装置市场（依应用）

  • 概述
  • 呼吸系统
    • 新生儿
    • 孩子们
    • 成人
  • 心肺復苏
    • 新生儿
    • 孩子们
    • 成人
  • 心
    • 新生儿
    • 孩子们
    • 成人

9. 全球体外膜氧合装置市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东和非洲
    • 阿拉伯聯合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲地区

第十章体外膜氧合装置市场的全球竞争格局

  • 概述
  • 企业市场排名
  • 公司地理分布
  • 公司产业布局
  • ACE矩阵

第十一章 公司简介

  • Medtronic
  • Fresenius Medical Care AG & Co. KGAA
  • Maquet Holding
  • Getinge Group
  • Microport
  • Origin Biomedical
  • Terumo Cardiovascular Systems Corporation
  • Livanova plc
  • Nipro Corporation
  • Euro sets SRL

第 12 章 已验证的市场情报

  • 关于已验证的市场情报
  • 动态资料视觉化
简介目录
Product Code: 40614

Extracorporeal Membrane Oxygenation Machine Market Valuation - 2026-2032

The growing advancements and the utilization of sophisticated sensor and monitoring systems enabling the real-time assessment and tracking of patient parameters is driving the growth of the Extracorporeal Membrane Oxygenation Machine Market. The growth of the healthcare industry, particularly in developing regions, is creating new opportunities for the ECMO market, surpassing USD 623.23 Million valued in 2024 to reach a valuation of around USD 932.81 Million by 2032.

In addition to this, the advancements in technology are enhancing the practice of healthcare professionals in the use of ECMO machines, thereby contributing to an increased utilization of these machines across diverse clinical environments. This technology is consequently leading to an increase in patient survival rates, enabling the niche market grow at a CAGR of 5.75% from 2026 to 2032.

Extracorporeal Membrane Oxygenation Machine Market: Definition/ Overview

The extracorporeal membrane oxygenation machine (ECMO) involves the external circulation of blood through a heart-lung machine. The device effectively eliminates carbon dioxide while delivering oxygen-enriched blood back to the circulatory system. The right side of the heart directs blood flow to the heart-lung machine. The substance is subsequently reheated and returned to the body.

ECMO works by channeling the patient's blood through an external circuit where it is oxygenated and carbon dioxide is removed before being returned to the body. It is commonly used in cases of severe cardiac failure, respiratory failure (such as ARDS or pneumonia), or post-cardiac surgery complications. ECMO is increasingly being applied in neonatal and pediatric care, where it has significantly improved survival rates for infants with congenital defects or severe respiratory distress. Its ability to temporarily take over the function of failing organs offers physicians a critical window to stabilize patients and address underlying causes of failure.

How are the Rising Incidence of Cardiac and Respiratory Conditions Propelling the Market Expansion?

The increasing prevalence of cardiopulmonary disorders is a significant issue, highlighting the necessity for enhanced medical interventions, including ECMO machines. Cardiac diseases, such as heart failure, myocardial infarction, and cardiac arrest, are on the rise due to factors like aging populations, sedentary lifestyles, poor diets, and increasing prevalence of risk factors such as hypertension, obesity, and diabetes. As these conditions often lead to life-threatening situations where traditional treatments may not suffice, ECMO systems are becoming essential in providing life support by maintaining oxygenation and circulatory functions while underlying conditions are treated.

Acute respiratory distress syndrome (ARDS) is characterized by the accumulation of fluid in the small air sacs of the lungs, impeding the efficient transfer of oxygen into the bloodstream. There is potential for escalation to severe respiratory issues, necessitating external assistance for effective breathing support. Cardiogenic shock represents a severe medical condition characterized by the heart's abrupt inability to effectively pump sufficient blood to meet the body's demands, leading to potential organ failure if not addressed promptly.

The rising patient population is leading to an escalating demand for ECMO machines. ECMO machines serve as substitutes for the heart and lungs, facilitating a period of rest and recovery for these vital organs. This technology has become essential in the intensive care unit for managing patients who do not respond to alternative treatments. The increasing prevalence of cardiopulmonary disorders is a significant factor influencing the ECMO machine market.

How Will the Elevated Expenses Associated with ECMO Machines and Procedures Hinder the Market Expansion?

The extracorporeal membrane oxygenation machine serves as a critical life support mechanism for individuals experiencing heart or lung failure. The core issue is that the substantial costs associated with ECMO machines, often reaching hundreds of thousands, represent a significant barrier to their utilization despite their remarkable capabilities. The procedure also requires highly specialized medical teams, including trained perfusionists, intensive care unit (ICU) staff, and continuous patient monitoring, which adds to labor costs and limits the number of hospitals capable of offering ECMO treatment.

This results from the utilization of cutting-edge technology and innovative materials in its production process. The overall cost is further influenced by the maintenance and operational expenses associated with these machines. ECMO procedures necessitate specialized teams of healthcare professionals, comprising surgeons, nurses, and percussionists, which contribute to the total treatment expenses.

Category-Wise Acumens

What are the Features Bolstering the Demand of Oxygenators Segment?

The oxygenators segment represented the most dominating segment in 2023 and is projected to continue its dominance throughout the forecast period. The rise in chronic diseases, particularly Chronic Obstructive Pulmonary Disease (COPD), alongside the growing need for heart and lung transplantation procedures, can explain this trend. The World Health Organization (WHO) reported that COPD ranked as the third leading cause of death worldwide, accounting for roughly 3.23 million fatalities. The significant increase in mortality rates associated with respiratory and cardiovascular diseases is driving the expansion of the Extracorporeal Membrane Oxygenation Machine Market.

The oxygenators segment is expected to benefit from the overall advancements in ECMO technology and its expanding use in broader clinical settings, including emergency and pediatric care. As healthcare systems adopt ECMO for more patients with severe cardiac and respiratory conditions, demand for high-performance oxygenators will likely increase. Furthermore, ongoing research into biocompatibility and longevity of oxygenators is set to improve patient outcomes and reduce the risks associated with long-term ECMO use, solidifying the market dominance of this segment.

How will the Demand for Veno-Arterial Segment Impacts the Market Growth?

The veno-arterial segment represented the fastest growing CAGR in 2023 and is projected to experience robust growth at a healthy CAGR throughout the forecast period. The increase in utilization can be linked to its effectiveness in managing cases of cardiac arrest, where it plays a crucial role in algorithm-driven life support techniques aimed at reestablishing blood circulation. The rising prevalence of chronic obstructive pulmonary disease (COPD) serves as a significant factor influencing this market segment. A research paper published by BMC Pulmonary Medicine in July 2022 indicated that around 300 million individuals are affected by COPD worldwide, with a prevalence rate of about 12.2%. This underscores a considerable demand for advanced life support technologies such as ECMO machines.

Innovations in VA-ECMO technology, such as more compact and efficient devices, and the integration of real-time monitoring systems, are likely to make it more accessible in emergency care and for long-term patient management. Moreover, expanding use in treating adult and pediatric patients with complex cardiac conditions, combined with advancements in postoperative recovery, will further drive the growth of this segment across hospitals and specialized care centers during the forecast period.

Country/Region-wise Acumens

How will the Growing Cardiac Issues Drives the Market in North America?

In 2023, the North America Extracorporeal Membrane Oxygenation Machine Market had the dominating share in terms of global revenues. North American market was predominantly represented by the U.S., which held the largest share in the global market. The nation possesses a robust healthcare infrastructure and a significant patient demographic in need of ECMO machines, attributed to the widespread occurrence of chronic illnesses and a notable rate of cardiac and respiratory failures. This has led to a higher demand for advanced life support systems like ECMO, particularly the veno-arterial (VA) type, which provides both cardiac and respiratory assistance in patients suffering from severe cardiac failure. With increasing numbers of patients requiring urgent intervention for heart-related complications, hospitals and medical centers are increasingly adopting ECMO technology as a critical tool for improving survival rates.

The U.S. has maintained its position as a global leader in the innovation of medical devices, drawing in leading manufacturers of ECMO machines. Major market players such as Medtronic, a prominent player in the medical technology sector, has achieved notable advancements in the ECMO machine market. The active participation of the U.S. in the development and approval processes for ECMO machines has led to a notable rise in adoption and expansion within this market segment.

How will the Increasing Adoption of Precision Medicine Supports the Market Growth in China?

Asia-Pacific region to grow at a robust CAGR during the forecast period. China is projected to maintain a leading role in the East Asia market for extracorporeal membrane oxygenation machines. The increasing utilization of ECMO in pediatric and neonatal care represents a significant factor influencing the industry in China. The evolving healthcare sector in the country is increasingly focused on improving clinical outcomes for infants and children suffering from life-threatening cardiorespiratory conditions.

In cases involving congenital heart defects, respiratory distress syndrome, and various severe infections in neonates, ECMO serves as a critical intervention when standard treatment options are inadequate. China is channeling investments into specialized pediatric and neonatal intensive care units across major hospitals, with ECMO machines emerging as essential equipment. The demand in China is driven by the government's dedication to enhancing health services for children, alongside the growing awareness among healthcare professionals regarding the effectiveness of ECMO in pediatric care.

Competitive Landscape

The Extracorporeal Membrane Oxygenation Machine Market is a dynamic and competitive landscape, with a mix of established players and emerging challengers vying for market share. These players are actively working to strengthen their presence by implementing strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are dedicated to continuously improving their product line to meet the needs of a wide range of customers in different regions.

Some of the key players operating in the Extracorporeal Membrane Oxygenation Machine Market include:

Medtronic, Fresenius Medical Care A.G. & Co. KGAA, Maquet Holding, Getinge Group, Microport, Origin Biomedical, Terumo Cardiovascular Systems Corporation, Livanova plc, Nipro Corporation, Euro sets S.R.L., Cytosorbents Corporation, Abiomed.

Latest Developments

In July 2023, the ASAIO Conference showcased BreathMo, an advanced ECMO system, highlighting China's innovation in the field of medical technology. This innovative maglev technology effectively meets the specific medical requirements of patients in China, representing a significant progression in the sector.

In April 2023, Abbott obtained two new approvals from the U.S. Food and Drug Administration (FDA) for its renowned life support system, specifically the CentriMag Blood Pump. The expanded FDA indication facilitates prolonged utilization in adults based on extracorporeal membrane oxygenation (ECMO), an essential life support technique for individuals experiencing cardiac and pulmonary complications.

In November 2022, LivaNova PLC announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation advanced circulatory support system, LifeSPARC. The approval indicates that the LifeSPARC system complies with the standards established by the FDA, allowing for its utilization in the U.S. market.

In July 2022, Inspira Technologies OXY B.H.N Ltd., a leader in life support technology, launched the "Liby" System. This sophisticated life support system is engineered to manage patients experiencing critical heart and lung failure.

In July 2021, Xenios AG, a subsidiary of Fresenius Medical Care, obtained approval from the National Medical Products Administration (NMPA) in China for the utilization of its Xenios Console and patient kits in ECMO therapy. The approval follows the successful registration of two patient kits in China.

Extracorporeal Membrane Oxygenation Machine Market, By Category

  • Component:
  • Pumps
  • Oxygenator
  • Controllers
  • Cannula
  • Accessories
  • Services:
  • Veno-Venous
  • Veno-Arterial
  • Arterio-Venous
  • Patient Type:
  • Neonates
  • Pediatric
  • Adult
  • Application:
  • Respiratory
  • Neonates
  • Pediatric
  • Adult
  • Cardiac
  • Neonates
  • Pediatric
  • Adult
  • ECPR
  • Neonates
  • Pediatric
  • Adult
  • Region:
  • North America
  • Asia-Pacific
  • Europe
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Extracorporeal Membrane Oxygenation Machine Market Geographical Analysis (CAGR %)
  • 3.6 Global Extracorporeal Membrane Oxygenation Machine Market, By Patient Type (USD Million)
  • 3.7 Global Extracorporeal Membrane Oxygenation Machine Market, By Application (USD Million)
  • 3.8 Global Extracorporeal Membrane Oxygenation Machine Market, By Modality (USD Million)
  • 3.9 Global Extracorporeal Membrane Oxygenation Machine Market, By Component (USD Million)
  • 3.10 Future Market Opportunities
  • 3.11 Global Market Split
  • 3.12 Product Life Line

4 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET OUTLOOK

  • 4.1 Global Extracorporeal Membrane Oxygenation Machine Evolution
  • 4.2 Drivers
    • 4.2.1 Driver1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY COMPONENT

  • 5.1 Overview
  • 5.2 Pumps
  • 5.3 Cannula
  • 5.4 Oxygenator
  • 5.5 Accessories
  • 5.6 Controller

6 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY SERVICES

  • 6.1 Overview
  • 6.2 Veno- Arterial
  • 6.3 Veno-Venous
  • 6.4 Arterio-Venous

7 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY PATIENT TYPE

  • 7.1 Overview
  • 7.2 Adult
  • 7.3 Pediatric
  • 7.4 Neonates

8 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY APPLICATION

  • 8.1 Overview
  • 8.2 Respiratory
    • 8.2.1 Neonates
    • 8.2.2 Pediatric
    • 8.2.3 Adult
  • 8.3 ECPR
    • 8.3.1 Neonates
    • 8.3.2 Pediatric
    • 8.3.3 Adult
  • 8.4 Cardiac
    • 8.4.1 Neonates
    • 8.4.2 Pediatric
    • 8.4.3 Adult

9 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 UAE
    • 9.6.2 Saudi Arabia
    • 9.6.3 South Africa
    • 9.6.4 Rest of Middle-East and Africa

10 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Ranking
  • 10.3 Key Developments
  • 10.4 Company Regional Footprint
  • 10.5 Company Industry Footprint
  • 10.6 ACE Matrix

11 COMPANY PROFILES

  • 11.1 Medtronic
    • 11.1.1 Company Overview
    • 11.1.2 Company Insights
    • 11.1.3 Product Benchmarking
    • 11.1.4 Key Developments
    • 11.1.5 Winning Imperatives
    • 11.1.6 Current Focus & Strategies
    • 11.1.7 Threat from Competition
    • 11.1.8 SWOT Analysis
  • 11.2 Fresenius Medical Care A.G. & Co. KGAA
    • 11.2.1 Company Overview
    • 11.2.2 Company Insights
    • 11.2.3 Product Benchmarking
    • 11.2.4 Key Developments
    • 11.2.5 Winning Imperatives
    • 11.2.6 Current Focus & Strategies
    • 11.2.7 Threat from Competition
    • 11.2.8 SWOT Analysis
  • 11.3 Maquet Holding
    • 11.3.1 Company Overview
    • 11.3.2 Company Insights
    • 11.3.3 Product Benchmarking
    • 11.3.4 Key Developments
    • 11.3.5 Winning Imperatives
    • 11.3.6 Current Focus & Strategies
    • 11.3.7 Threat from Competition
    • 11.3.8 SWOT Analysis
  • 11.4 Getinge Group
    • 11.4.1 Company Overview
    • 11.4.2 Company Insights
    • 11.4.3 Product Benchmarking
    • 11.4.4 Key Developments
    • 11.4.5 Winning Imperatives
    • 11.4.6 Current Focus & Strategies
    • 11.4.7 Threat from Competition
    • 11.4.8 SWOT Analysis
  • 11.5 Microport
    • 11.5.1 Company Overview
    • 11.5.2 Company Insights
    • 11.5.3 Product Benchmarking
    • 11.5.4 Key Developments
    • 11.5.5 Winning Imperatives
    • 11.5.6 Current Focus & Strategies
    • 11.5.7 Threat from Competition
    • 11.5.8 SWOT Analysis
  • 11.6 Origin Biomedical
    • 11.6.1 Company Overview
    • 11.6.2 Company Insights
    • 11.6.3 Product Benchmarking
    • 11.6.4 Key Developments
    • 11.6.5 Winning Imperatives
    • 11.6.6 Current Focus & Strategies
    • 11.6.7 Threat from Competition
    • 11.6.8 SWOT Analysis
  • 11.7 Terumo Cardiovascular Systems Corporation
    • 11.7.1 Company Overview
    • 11.7.2 Company Insights
    • 11.7.3 Product Benchmarking
    • 11.7.4 Key Developments
    • 11.7.5 Winning Imperatives
    • 11.7.6 Current Focus & Strategies
    • 11.7.7 Threat from Competition
    • 11.7.8 SWOT Analysis
  • 11.8 Livanova plc
    • 11.8.1 Company Overview
    • 11.8.2 Company Insights
    • 11.8.3 Product Benchmarking
    • 11.8.4 Key Developments
    • 11.8.5 Winning Imperatives
    • 11.8.6 Current Focus & Strategies
    • 11.8.7 Threat from Competition
    • 11.8.8 SWOT Analysis
  • 11.9 Nipro Corporation
    • 11.9.1 Company Overview
    • 11.9.2 Company Insights
    • 11.9.3 Product Benchmarking
    • 11.9.4 Key Developments
    • 11.9.5 Winning Imperatives
    • 11.9.6 Current Focus & Strategies
    • 11.9.7 Threat from Competition
    • 11.9.8 SWOT Analysis
  • 11.10 Euro sets S.R.L.
    • 11.10.1 Company Overview
    • 11.10.2 Company Insights
    • 11.10.3 Product Benchmarking
    • 11.10.4 Key Developments
    • 11.10.5 Winning Imperatives
    • 11.10.6 Current Focus & Strategies
    • 11.10.7 Threat from Competition
    • 11.10.8 SWOT Analysis

12 VERIFIED MARKET INTELLIGENCE

  • 12.1 About Verified Market Intelligence
  • 12.2 Dynamic Data Visualization